ECU
JAZZ icon

Eisler Capital (UK)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Eisler Capital (UK)’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,382
Closed -$1.52M – 661
2023
Q4 		$1.52M Buy
+12,382
New +$1.55M 0.01% 430

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Eisler Capital (UK)'s JAZZ Position: Q1 2024 in Review

Eisler Capital (UK) sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2024, closing a stake of 12,382 shares — an estimated $1.52M sold.

Eisler Capital (UK) first reported a position in JAZZ in Q4 2023 and held it in 1 quarter. The position peaked at $1.52M in Q4 2023. 480 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.

  • Eisler Capital (UK) reported no remaining Jazz Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Eisler Capital (UK) sold 12,382 Jazz Pharmaceuticals shares in Q1 2024, an estimated $1.52M.
  • Eisler Capital (UK) first reported a position in Jazz Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Eisler Capital (UK)'s Jazz Pharmaceuticals position peaked at $1.52M in Q4 2023.
  • 480 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.

Based on Eisler Capital (UK)'s 13F filing for Q1 2024, filed 14 May 2024.